Product Description

🔹 Product Overview
Egrifa Injection is a prescription injectable medicine containing Tesamorelin, a synthetic analogue of growth hormone-releasing factor (GHRF). It is used under specialist medical supervision for specific medical conditions related to abnormal fat distribution.
Tesamorelin works by stimulating the pituitary gland to release growth hormone, which influences metabolism and body fat regulation. Egrifa is not approved as a general weight-loss medicine and should only be used for approved medical indications.

🔹 Key Uses
Egrifa Injection may be prescribed for:
Reduction of excess abdominal fat associated with HIV-related lipodystrophy in eligible adult patients
Management of abnormal visceral fat accumulation under specialist care
Supporting metabolic management in specific clinical conditions
Use depends on the patient’s medical history, diagnosis, and physician evaluation.

🔹 Composition
Active Ingredient:
Tesamorelin (as Tesamorelin acetate)
Drug Class:
Growth hormone-releasing factor (GHRF) analogue
Dosage Form:
Injectable powder for subcutaneous administration
Therapeutic Category:
Metabolic and hormonal therapy

🔹 How It Works
Egrifa Injection works by:
Mimicking the action of natural growth hormone-releasing factor
Stimulating the pituitary gland to release growth hormone
Increasing growth hormone-related metabolic activity
Influencing fat metabolism and reduction of visceral abdominal fat in appropriate patients
Tesamorelin acts through the growth hormone pathway and is not intended to directly replace growth hormone therapy.

🔹 Key Benefits
Potential benefits of Egrifa Injection may include:
Helps reduce excess abdominal visceral fat in suitable patients
Targets abnormal fat accumulation related to specific medical conditions
Provides a targeted hormonal approach under specialist supervision
Administered through a controlled injectable treatment plan

🔹 Dosage and Administration
Egrifa Injection should be used only under a doctor’s supervision.
It is administered by subcutaneous injection as directed.
The injection is commonly given in the abdominal area with rotation of injection sites.
Dose and treatment duration depend on the prescribed formulation and patient condition.
Do not self-adjust the dose without medical advice.
The approved dosing instructions vary by formulation, so healthcare professionals should follow the specific product information.

🔹 Possible Side Effects
Common side effects may include:
Injection-site reactions
Redness, swelling, or irritation at the injection area
Joint pain
Muscle pain
Headache
Fluid retention
Increased blood sugar levels
Seek medical advice if you experience:
Severe allergic reactions
Significant swelling
Persistent joint or muscle problems
Symptoms of high blood sugar
Vision changes

🔹 Precautions
Before using Egrifa Injection:
Inform your doctor about diabetes or blood sugar problems.
Tell your doctor if you have a history of cancer or active malignancy.
Discuss pituitary gland disorders or hormonal conditions.
Inform your doctor about all medicines and supplements you use.
Not recommended during pregnancy.
Use only under specialist medical supervision.